flecainide / Generic mfg. - LARVOL DELTA

Environmental Contaminants in Surface Snow Samples Made from Reclaimed Water at a Ski Resort: A Mass Spectrometry Analysis. (PubMed, ACS Environ Au) - "Nineteen pharmaceuticals were found to be increased in high artificial snowmaking samples as compared to natural snow, including carbamazepine, fexofenadine, flecainide, and lamotrigine, which were present at low ng/L concentrations in one set of high artificial snowmaking samples. A suite of inorganic contaminants was also assessed and quantified using inductively coupled plasma mass spectrometry to reveal that nine metalssodium, phosphorus, potassium, chromium, manganese, iron, zinc, arsenic, and bariumwere increased in abundance in high artificial snowmaking samples compared to levels in normal snow. Taken together, this study suggests that snow made from reclaimed water may contain anthropogenic organic and inorganic analytes, warranting further study on their environmental and human health effects."

Journal

Delayed-Onset Flecainide-Induced Liver Injury Presenting With Cholangiolitis (ACG 2026) - "Recognition of flecainide-associated hepatotoxicity is important as hepatic dysfunction may increase flecainide exposure and risk of proarrhythmic complications. Increased awareness of this rare hepatotoxicity may help facilitate early diagnosis, prompt discontinuation of the drug, and prevent invasive evaluation."

Atrial Fibrillation • Autoimmune Hepatitis • Cardiovascular • Cholestasis • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure

Swallowing-Induced Supraventricular Tachycardia Associated With Reflux Esophagitis (ACG 2026) - "The patient was started on flecainide, metoprolol succinate, and diltiazem and discharged with mobile cardiac outpatient telemetry (MCOT). Figure: Figure 1. Mobile cardiac outpatient telemetry demonstrating initiation of paroxysmal supraventricular tachycardia (197 beats/min) temporally associated with swallowing, supporting the diagnosis of swallowing-induced supraventricular tachycardia."

Barrett Esophagus • Cardiovascular • CNS Disorders • Coronary Artery Disease • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Infectious Disease • Pulmonary Disease • Ventricular Tachycardia

CAAD-PVC: Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes (clinicaltrials.gov) - P=N/A | N=50 | Recruiting | Sponsor: Western Sydney Local Health District | Not yet recruiting ➔ Recruiting

Enrollment open

Effects of Flecainide Therapy on Cardiac Device Performance: A Prospective Multicenter Longitudinal Study. (PubMed, Heart Rhythm) - No abstract available

Journal • Observational data

Atrial fibrillation : An overview of the various treatment options (PubMed, Herz) - "Electrical cardioversion is particularly suitable for the acute treatment of hemodynamically unstable patients, while pharmacological treatment and catheter ablation represent long-term treatment approaches. Class IC antiarrhythmic drugs such as flecainide and propafenone are contraindicated in patients with structural heart disease."

Journal • Atrial Fibrillation • Cardiovascular • Heart Failure • Ischemic stroke

Flecainide- and isoproterenol-induced alterations in heart rate variability and DFA-derived physiological complexity in anesthetized mice. (PubMed, BMC Cardiovasc Disord) - "Flecainide and isoproterenol produced distinct alterations in cardiac rhythm dynamics in anesthetized mice. DFAα1 and DFA-derived area-based indices, particularly dS1 and TdS, provided complementary information about drug-induced changes in RR interval fractal organization. These findings should be interpreted as exploratory evidence of altered rhythm organization rather than as diagnostic evidence of specific arrhythmia types or cardiac health status."

Journal • Preclinical • Anesthesia • Cardiovascular

Dronedarone vs class Ic agents for early AF: Protocol for the DRIVE-AF randomized clinical trial. (PubMed, Heart Rhythm O2) - P4 | "Participants will be randomized (1:1) to receive either dronedarone (400 mg twice daily) or standard-of-care class Ic agents (flecainide or propafenone) for 12 months. By establishing comparative efficacy and safety, this study aims to refine international standards for pharmacologic rhythm control in early AF. ClinicalTrials.gov identifier: NCT07270848."

Clinical • Journal • Atrial Fibrillation • Cardiovascular

Sodium-channel blocker challenge unmasks Brugada syndrome in a 54-year-old male presenting with recurrent syncope and chronic cannabis use. (PubMed, HeartRhythm Case Rep) - No abstract available

Journal • Cardiovascular • Genetic Disorders

"A better system" - managing the adverse effects of prescribed medicines: Cluster-randomised controlled trial and process evaluation of the ADRe Profile in primary care. (PubMed, PLoS One) - P=N/A | "The ADRe Profile benefited patients by reducing risk of suboptimal prescribing and iatrogenic harm. The project is registered with the Clinicaltrials.gov as NCT04663360 (https://clinicaltrials.gov/study/NCT04663360)."

Adverse events • Clinical • Journal • Pain

Diagnostic and therapeutic challenges in Andersen-Tawil syndrome. (PubMed, Heart Rhythm) - "β-blockers and flecainide are commonly used while implantable cardioverter-defibrillators are reserved for high-risk cases. Potassium supplementation and acetazolamide should be considered in selected patients with periodic paralysis. Given incomplete penetrance and absence of validated risk stratification tools, careful multidisciplinary evaluation and individualised management are essential."

Journal • Review • Cardiovascular • Ventricular Tachycardia

A NARROW WINDOW, A WIDE QRS: FLECAINIDE TOXICITY UNVEILED (CHEST 2026) - No abstract available

Cardiovascular

FROM RHYTHM CONTROL TO RESPIRATORY FAILURE: FLECAINIDE-INDUCED LUNG INJURY MASQUERADING AS ARDS (CHEST 2026) - No abstract available

Acute Respiratory Distress Syndrome • Respiratory Diseases

POSTNATAL WIDE-COMPLEX TACHYCARDIA AND FLECAINIDE FAILURE IN NEONATAL SVT: A CRITICAL CARE CASE REPORT (CHEST 2026) - No abstract available

Case report • Clinical • Cardiovascular • Critical care

Flecainide Reduces Exercise-Induced Arrhythmic Burden in PKP2-Related Arrhythmogenic Cardiomyopathy. (PubMed, Europace) - No abstract available

Journal • Cardiomyopathy • Cardiovascular

ReCAST AF: Flecainide Safety in Patients With Coronary Artery Disease and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=988 | Recruiting | Sponsor: Universitaire Ziekenhuizen KU Leuven | Not yet recruiting ➔ Recruiting

Enrollment open • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease

Beyond pooled analysis: sex-specific cardiovascular adverse event reporting signals with antiarrhythmic drugs in FAERS. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "Sex-stratified analysis uncovered "hidden" associations undetected in pooled data, including propafenone-QT prolongation in men and amiodarone-QT prolongation in women. Adverse event profiles were often drug-specific and opposing: cardiogenic shock showed higher reporting odds among males for sotalol, whereas flecainide showed higher reporting odds in females...Sex-specific CV-AE profiles reporting patterns are often masked in pooled analyses, underscoring the need for sex-stratified pharmacovigilance to guide personalized antiarrhythmic therapy. The identified associations should be considered hypothesis-generating and require validation in datasets with richer clinical information."

Adverse events • Journal • Retrospective data • Cardiovascular

Differences in analytical approach during conduction velocity analysis of optically mapped hearts affect reported data and conclusions. (PubMed, Comput Methods Programs Biomed) - "Vector inclusion parameters substantially influence reported conduction velocity and anisotropy, and can alter statistical conclusions. A constraint-based, parsimonious approach to parameter selection improves robustness and transparency without invoking optimization, providing a framework adaptable to other analytical workflows lacking ground truth."

Journal • Cardiovascular

Electrocardiogram As A Canary: A Case Of Cardiogenic Shock From Flecainide Toxicity [Poster no. 446] (HFSA 2026) - No abstract available

Clinical • Cardiovascular

Comparative Effectiveness of Propranolol versus Flecainide/Sotalol for Supraventricular Tachycardia Prophylaxis in Children Aged 1-17 Years: A Multicenter Retrospective Cohort Study (AHA 2026) - "Abstract is embargoed at this time."

HEOR • Retrospective data • Cardiovascular • Ventricular Tachycardia

The Effect of Psychotropic Agents on Sick Sinus Syndrome: A Case Report. (PubMed, Cureus) - "A review of her regimen identified several cardiac safety concerns: quetiapine's potential interference with flecainide, hydroxyzine-associated QT prolongation, and bupropion's CYP2D6 inhibition that could increase flecainide levels. Management prioritized minimizing arrhythmogenic risk by discontinuing quetiapine, restricting hydroxyzine to low doses, and continuing melatonin, supplemented by stress testing and reassessment of psychotropic options. This case highlights the importance of careful psychotropic selection in patients with SSS, favoring lower-risk agents, such as mirtazapine, which is one of the safest among several possible alternatives, while maintaining close ECG monitoring and coordinated cardiology and psychiatry collaboration to reduce drug-drug interactions and optimize safety."

Journal • Cardiovascular • CNS Disorders • General Anxiety Disorder • Insomnia • Mood Disorders • Psychiatry • Sleep Disorder • Ventricular Tachycardia

Pharmaceutical pollution in a wastewater-impacted coastal ecosystem. (PubMed, Environ Pollut) - "Out of 95 target analytes, 15 were detected, with the most frequent detections being telmisartan (83%), flecainide (52%), memantine (37%), caffeine (28%) and tramadol (23%). Follow-up sampling revealed higher pharmaceutical concentrations in sea foam relative to seawater, suggesting enrichment within the air-water interface and potential transport to terrestrial environments via coastal aerosols. Overall, our findings demonstrate the role of wastewater in pharmaceutical pollution, with plants and algae emerging as potential bioindicators."

Journal

Essential antiarrhythmic drug accessibility worldwide: A multi-survey study and comprehensive evaluation of access and supply challenges. (PubMed, Europace) - "Physicians worldwide frequently encounter problems accessing guideline recommended antiarrhythmic drugs for their patients, which putatively impacts on their patients' quality of life and life expectancy. This highlights systemic vulnerabilities that extend across national and institutional boundaries, urging close collaboration among clinicians, policymakers, manufacturers, and institutions to guarantee timely and equitable treatment for all patients."

Journal • Cardiovascular • Pediatrics

SCN5A H558R polymorphism reduces the risk of flecainide-related toxicity and inefficacy (ESC 2026) - "Regarding antiarrhythmic drug (AAD) therapy, 12 (13.2%) received no AADs, 32 (35.2%) amiodarone, and 47 (51.6%) flecainide. This study corroborates that H558R+/- carriers have better clinical outcomes on flecainide post-ECV. By validating these findings in a representative, real-world cohort—encompassing diverse comorbidities and flexible flecainide dosing schemes—our study overcomes the limitations of previous research restricted to highly selected populations. Crucially, we demonstrate a specific pharmacogenetic interaction: the H558R+/- genotype offers no advantage with alternative AADs."

Clinical • Cardiovascular • Heart Failure

Peak atrial longitudinal strain in predicting recurrence of atrial fibrillation after cardioversion (ESC 2026) - "Patients were excluded if they did not have adequate pre-cardioversion cardiac ultrasound imaging, were in sinus rhythm during the echo or were taking antiarrhythmics such as amiodarone or flecainide. Pre-cardioversion PALS strongly is associated with increased rates of early AF recurrence following cardioversion. Its use in the clinical setting can be used to improve patient selection and individualised rhythm control strategies, thereby avoiding unnecessary cardioversions for patients and freeing up resources."

Atrial Fibrillation • Cardiovascular